Drugmaker Eli Lilly and Co. said a federal court judge upheld a patent protecting one of its best-selling drugs, the cancer treatment Alimta.

A trial on the drug's compound patent, which protects its chemical makeup, started Nov. 8 and ended Monday with a ruling from the U.S. District Court for the District of Delaware, Lilly said.

For the full BusinessWeek story, click here.